| OCR Text |
Show Neuro-Ophthalmology News Section Editors: Kathleen B. Digre, MD Meagan D. Seay, DO The American Headache Society Met in Denver, June 9, 2022 T he American Headache Society met in Denver at the Gaylord Hotel and Conference Center; it was the first in person Annual Scientific meeting since 2019. With over 1,078 registrants, including 800 in-person attendees, there were 302 abstracts including 237 posters and 24 oral presentations, and late-breaking abstracts. Many of the lectures would be helpful to neuro-ophthalmologists. One session included psychedelics and hallucinogens including psilocybin to treat depression, anxiety, and headache. These agents may actually change neuroplasticity. We are likely to hear more about this rising class of drugs. One session was dedicated to what makes migraine worse including depression, sleep disorder, medication overuse, and obesity. With the rising prevalence of obesity in our country, and the obvious intersection with idiopathic intracranial hypertension (IIH), this topic was timely. The conference focused on treatment of migraine. One interesting study showed that atogepant (now approved for migraine prevention; see Ref. 1) had weight loss as a side effect. This may be a promising therapy for migraine associated with IIH (1). Other presentations that would be of interest to neuroophthalmologists include: 1) The use of vagal nerve stimulation for the treatment of visual snow. In this study; 3 patients were treated with noninvasive vagal nerve stimulation, 2 two-minute stimulations twice daily for 10–12 weeks. Two of the 3 had marked relief of visual snow symptoms. This deserves further study (Poster 183, Arca KN, Vanderpluym J from the Mayo clinic). e606 2) Headache is closely related to reduced visual quality of life in IIH, so finding treatments for IIH headache would be important to all of us. One retrospective study was presented showing that although calcitonin gene-related peptide monoclonal antibody treatment is attractive, it was not effective (Poster 119, Frerichs L, Nandy K, Friedman DI). 3) A large Migraine Clinical Outcome Assessment System (MiCOAS) study described migraine symptoms throughout the headache cycle. Not surprisingly, eye symptoms were very common—especially eye pain before, during, and after headache pain (Poster P 29: Non-ICHD-3 defining migraine symptoms by phase of the migraine cycle: Results of the MiCOAS qualitative study. Gerstein MT, McGinley JS, Houts CR, Buse DC, Nishida T, Wirth R, Uzumcu AA, McCarrier K, Cooke A, Touba N, Lipton RB). 4) Causes of photophobia in children at one tertiary eye center revealed that 1/3 of children had migraine as the cause, with eyelid inflammation being very common too. Surprisingly, almost 1/3 left the office without a diagnosis for their photophobia. Poster 115: Arbon J, Caskey E, Digre KB, Katz BJ, Seay M, Crum AV, Warner JE. Kathleen B. Digre, MD Meagan D. Seay, DO Departments of Ophthalmology and Neurology, Moran Eye Center, University of Utah, Salt Lake City, Utah REFERENCE 1. Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706. Digre and Seay: J Neuro-Ophthalmol 2022; 42: e606 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. |
